No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks (New B) venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2wk	venetoclax + obinutuzumab Sensitive: A1 - Approval N Engl J Med - 2 weeks venetoclax + obinutuzumab Sensitive : A1 N Engl J Med - 2 weeks - (New B)
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks (New C3) acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2wk	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials EHA 2023 - 2 weeks acalabrutinib + KRT-232 Sensitive : C3 EHA 2023 - 2 weeks - (New C3)
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) ibrutinib + brusatol Sensitive : D EHA 2023 - 2wk	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks ibrutinib + brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
KEAP1 expression	Chronic Lymphocytic Leukemia	KEAP1 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) brusatol Sensitive : D EHA 2023 - 2wk	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) ibrutinib + brusatol Sensitive : D EHA 2023 - 2wk	ibrutinib + brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks ibrutinib + brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
NFE2L2 expression	Chronic Lymphocytic Leukemia	NFE2L2 expression	Chronic Lymphocytic Leukemia	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks (New D) brusatol Sensitive : D EHA 2023 - 2wk	brusatol Sensitive: D – Preclinical EHA 2023 - 2 weeks brusatol Sensitive : D EHA 2023 - 2 weeks - (New D)
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1	ibrutinib + rituximab Sensitive: A1 - Approval ibrutinib + rituximab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1	orelabrutinib Sensitive: A1 - Approval orelabrutinib Sensitive : A1
CD20 expression	Chronic Lymphocytic Leukemia	CD20 expression	Chronic Lymphocytic Leukemia	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1	rituximab-arrx Sensitive: A1 - Approval rituximab-arrx Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1	Rixathon (rituximab biosimilar) Sensitive: A1 - Approval Rixathon (rituximab biosimilar) Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1	rituximab-pvvr Sensitive: A1 - Approval rituximab-pvvr Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1	ibrutinib + obinutuzumab Sensitive: A1 - Approval ibrutinib + obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	ofatumumab Sensitive: A1 - Approval ofatumumab Sensitive : A1	ofatumumab Sensitive: A1 - Approval ofatumumab Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1	rituximab Sensitive: A1 - Approval rituximab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1	rituximab/hyaluronidase Sensitive: A1 - Approval rituximab / hyaluronidase Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1	ibrutinib Sensitive: A1 - Approval ibrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1	obinutuzumab + acalabrutinib Sensitive: A1 - Approval obinutuzumab + acalabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1	obinutuzumab Sensitive: A1 - Approval obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1	acalabrutinib Sensitive: A1 - Approval acalabrutinib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	alemtuzumab Sensitive: A1 - Approval alemtuzumab Sensitive : A1	alemtuzumab Sensitive: A1 - Approval alemtuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1

Chronic Lymphocytic Leukemia

Associations(297)

Associations
(297)